<DOC>
	<DOCNO>NCT00088972</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . The use celecoxib may effective prevent breast cancer . PURPOSE : This randomized phase II trial study well celecoxib work prevent breast cancer premenopausal woman risk develop disease .</brief_summary>
	<brief_title>S0300 , Celecoxib Preventing Breast Cancer Premenopausal Women</brief_title>
	<detailed_description>OBJECTIVES : - Compare 1-year mammographic density premenopausal woman high risk develop breast cancer treat celecoxib v placebo . - Compare 1-year proliferation breast epithelial cell , measure Ki67 staining , patient treat drug . - Compare expression biomarkers , include cyclo-oxygenase-2 ( COX-2 ) enzyme marker apoptosis , breast tissue patient treat drug . - Compare 1-year plasma level insulin-like growth factor ( IGF ) -1 , IGF bind protein-3 , prostaglandin E_2 patient treat drug . - Compare toxicity drug patient . OUTLINE : This randomize , placebo-controlled , double-blind , multicenter study . Patients stratify accord risk category ( lobular carcinoma situ ductal carcinoma situ v BRCA1/2 mutation AND Gail risk v Gail risk ≥1.7 % &lt; 5 % v Gail risk ≥ 5 % ) prior tamoxifen use ( yes v ) . Patients randomize 1 2 treatment arm . - Celocoxib : Patients receive oral celecoxib twice daily . - Placebo : Patients receive oral placebo twice daily . In arm , treatment continue 12 month absence unacceptable toxicity diagnosis cancer . Patients follow 1 month . PROJECTED ACCRUAL : A total 100 patient ( 50 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : At elevate risk develop breast cancer , define 1 following : Modified Gail risk 5 year ≥ 1.7 % lifetime risk ≥ 20 % AND Claus Model , BRCAPro Model , TyrerCuzick Model lifetime risk ≥ 20 % Diagnosis lobular carcinoma situ ductal carcinoma situ Known deleterious mutation BRCA1 BRCA2 At least 1 breast available imagery biopsy Has undergone baseline mammogram standard density wedge within 714 day completion last menstrual period AND within 7 day study entry Mammogram normal benign ( BIRADS score 0 1 ) Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status Premenopausal , define 1 follow criterion : Last menstrual period &lt; 6 month ago AND prior bilateral ovariectomy AND estrogen replacement therapy Prior hysterectomy ( ovary still place ) AND normal folliclestimulating hormone level within 28 day study entry Performance status Zubrod 01 Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin &lt; 2.0 time institutional upper limit normal ( IULN ) SGOT SGPT &lt; 2 time IULN Alkaline phosphatase &lt; 2 time IULN INR ≤ 1.5 PT PTT ≤ IULN Renal Serum creatinine &lt; 2.0 time IULN Cardiovascular No history myocardial infarction No angina pectoris No known coronary artery disease No history stroke ministroke ( e.g. , transient ischemic attack ) No history thromboembolic disease ( e.g. , deep vein thrombosis pulmonary embolism ) No uncontrolled hypertension ( i.e. , blood pressure &gt; 140/90 mmHg ) Pulmonary No asthma take aspirin NSAIDs Other No known sensitivity celecoxib No allergy sulfonamides No urticaria allergictype reaction take aspirin NSAIDs No extreme lactose intolerance No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , early bladder cancer ( preinvasive transitional cell carcinoma bladder ) Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy More 5 year since prior biologic therapy cancer Chemotherapy More 5 year since prior chemotherapy cancer Endocrine therapy At least 28 day since prior tamoxifen No prior systemic estrogen modifier ( SERMs ) aromatase inhibitor Concurrent hormonal contraception ( i.e. , pill , patch , shot ) allow provide contraception initiate prior study entry Radiotherapy No prior radiotherapy breast study Surgery Not specify Other At least 7 day since prior anticoagulant therapy More 1 month since prior chronic daily aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) 7 day duration Concurrent intermittent aspirin NSAIDs allow ( 10 day per month ) No concurrent participation another clinical trial treatment prevention cancer unless long receive treatment followup phase</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>breast cancer situ</keyword>
	<keyword>lobular breast carcinoma situ</keyword>
	<keyword>ductal breast carcinoma</keyword>
</DOC>